Total Payments
$20,075
2024 Payments
$8,617
Companies
9
Transactions
37
Medicare Patients
784
Medicare Billing
$164,976
Payment Breakdown by Category
Other$10,365 (51.6%)
Consulting$4,144 (20.6%)
Travel$3,853 (19.2%)
Food & Beverage$1,638 (8.2%)
Education$75.60 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,660 | 2 | 33.2% |
| Consulting Fee | $4,144 | 1 | 20.6% |
| Travel and Lodging | $3,853 | 8 | 19.2% |
| Honoraria | $3,705 | 2 | 18.5% |
| Food and Beverage | $1,638 | 18 | 8.2% |
| Education | $75.60 | 6 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $5,426 | 6 | $0 (2024) |
| ARRAY BIOPHARMA INC | $4,883 | 4 | $0 (2023) |
| GENZYME CORPORATION | $4,362 | 6 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,802 | 10 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $1,500 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $523.46 | 4 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $283.35 | 3 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $262.19 | 2 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $32.40 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,617 | 19 | Ipsen Biopharmaceuticals, Inc ($5,426) |
| 2023 | $2,979 | 6 | ARRAY BIOPHARMA INC ($2,678) |
| 2022 | $2,322 | 2 | ARRAY BIOPHARMA INC ($2,205) |
| 2021 | $1,500 | 1 | CATALYST PHARMACEUTICALS, INC. ($1,500) |
| 2020 | $114.12 | 1 | Merck Sharp & Dohme Corporation ($114.12) |
| 2019 | $4,510 | 7 | GENZYME CORPORATION ($4,362) |
| 2018 | $32.40 | 1 | E.R. Squibb & Sons, L.L.C. ($32.40) |
All Payment Transactions
37 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,140.00 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $807.29 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $190.63 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $76.81 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Travel and Lodging | In-kind items and services | $64.00 | General |
| Category: Oncology | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Education | In-kind items and services | $12.60 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $146.91 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $119.54 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $1,035.00 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $791.16 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $771.66 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | FRUZAQLA (Drug) | Travel and Lodging | In-kind items and services | $128.85 | General |
| Category: ONCOLOGY | ||||||
| 01/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 01/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 12/19/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,520.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 05/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $149.57 | General |
| Category: Oncology | ||||||
| 05/19/2023 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 01/21/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $133.92 | General |
| 01/21/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Food and Beverage | In-kind items and services | $55.44 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 168 | 315 | $162,639 | $34,707 |
| 2022 | 4 | 159 | 285 | $142,693 | $31,398 |
| 2021 | 8 | 212 | 394 | $168,970 | $46,221 |
| 2020 | 9 | 245 | 522 | $203,355 | $52,650 |
Total Patients
784
Total Services
1,516
Medicare Billing
$164,976
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 60 | 158 | $88,478 | $18,436 | 20.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 66 | $27,084 | $6,562 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $29,806 | $5,818 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 21 | $7,504 | $1,624 | 21.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 17 | 17 | $4,819 | $1,144 | 23.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 13 | 15 | $4,948 | $1,122 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 133 | $71,477 | $16,242 | 22.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 40 | 40 | $29,752 | $6,136 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 64 | $25,328 | $5,364 | 21.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 37 | 48 | $16,136 | $3,656 | 22.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 50 | 119 | $62,131 | $14,931 | 24.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 16 | 51 | $8,466 | $8,193 | 96.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 44 | 44 | $31,752 | $7,179 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 37 | 71 | $22,927 | $6,175 | 26.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 53 | $20,522 | $4,626 | 22.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $13,532 | $2,764 | 20.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 17 | 22 | $4,854 | $1,235 | 25.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 18 | $4,786 | $1,118 | 23.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 130 | $48,310 | $11,740 | 24.3% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 13 | 63 | $10,458 | $10,118 | 96.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 36 | 98 | $49,262 | $9,563 | 19.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 46 | 46 | $31,955 | $6,674 | 20.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 27 | 27 | $20,437 | $4,766 | 23.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 31 | 65 | $20,387 | $4,532 | 22.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 52 | $13,252 | $3,251 | 24.5% |
About Ardaman Shergill
Ardaman Shergill is a Medical Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/16/2009. The National Provider Identifier (NPI) number assigned to this provider is 1992948152.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ardaman Shergill has received a total of $20,075 in payments from pharmaceutical and medical device companies, with $8,617 received in 2024. These payments were reported across 37 transactions from 9 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($6,660).
As a Medicare-enrolled provider, Shergill has provided services to 784 Medicare beneficiaries, totaling 1,516 services with total Medicare billing of $164,976. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Chicago, IL
- Active Since 04/16/2009
- Last Updated 10/24/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1992948152
Products in Payments
- Onivyde (Drug) $5,426
- BRAFTOVI (Drug) $4,780
- LIBTAYO (Drug) $4,362
- FRUZAQLA (Drug) $2,802
- FIRDAPSE (Drug) $1,500
- Vitrakvi (Drug) $283.35
- KEYTRUDA (Biological) $262.19
- IMFINZI (Biological) $119.54
- MEKTOVI (Drug) $102.95
- OPDIVO (Biological) $32.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Chicago
William Gradishar, Md, MD
Medical Oncology — Payments: $375,750
Medical Oncology $375,750
Sunandana Chandra, M.d, M.D
Medical Oncology — Payments: $372,888
Medical Oncology $372,888
Ruta Rao, M.d, M.D
Medical Oncology — Payments: $367,954
Medical Oncology $367,954
James Wallace
Medical Oncology — Payments: $340,782
Medical Oncology $340,782
Andrzej Jakubowiak
Medical Oncology — Payments: $318,488
Medical Oncology $318,488
Mary Fidler, M.d, M.D
Medical Oncology — Payments: $287,123
Medical Oncology $287,123